DE69933049T2 - Pharmazeutische zusammensetzung und verwendung von rnsaid zur behandlung der entzündung - Google Patents

Pharmazeutische zusammensetzung und verwendung von rnsaid zur behandlung der entzündung Download PDF

Info

Publication number
DE69933049T2
DE69933049T2 DE69933049T DE69933049T DE69933049T2 DE 69933049 T2 DE69933049 T2 DE 69933049T2 DE 69933049 T DE69933049 T DE 69933049T DE 69933049 T DE69933049 T DE 69933049T DE 69933049 T2 DE69933049 T2 DE 69933049T2
Authority
DE
Germany
Prior art keywords
nsaid
cox
flurbiprofen
dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69933049T
Other languages
German (de)
English (en)
Other versions
DE69933049D1 (de
Inventor
J. William Ojai WECHTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Loma Linda University
Original Assignee
Loma Linda University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22517175&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69933049(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Loma Linda University filed Critical Loma Linda University
Application granted granted Critical
Publication of DE69933049D1 publication Critical patent/DE69933049D1/de
Publication of DE69933049T2 publication Critical patent/DE69933049T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69933049T 1998-09-03 1999-09-03 Pharmazeutische zusammensetzung und verwendung von rnsaid zur behandlung der entzündung Revoked DE69933049T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14639598A 1998-09-03 1998-09-03
US146395 1998-09-03
PCT/US1999/020261 WO2000013684A2 (en) 1998-09-03 1999-09-03 Pharmaceutical composition and method for treatment of inflammation

Publications (2)

Publication Number Publication Date
DE69933049D1 DE69933049D1 (de) 2006-10-12
DE69933049T2 true DE69933049T2 (de) 2007-10-04

Family

ID=22517175

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69933049T Revoked DE69933049T2 (de) 1998-09-03 1999-09-03 Pharmazeutische zusammensetzung und verwendung von rnsaid zur behandlung der entzündung

Country Status (13)

Country Link
US (1) US6472433B2 (https=)
EP (1) EP1143958B8 (https=)
JP (1) JP2002524415A (https=)
CN (1) CN1391470A (https=)
AT (1) ATE353010T1 (https=)
AU (1) AU6026099A (https=)
CA (1) CA2342628C (https=)
CY (1) CY1106541T1 (https=)
DE (1) DE69933049T2 (https=)
DK (1) DK1143958T3 (https=)
ES (1) ES2281981T3 (https=)
PT (1) PT1143958E (https=)
WO (1) WO2000013684A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
JP2002533379A (ja) 1998-12-23 2002-10-08 イデア アクチェンゲゼルシャフト 生体内における局所的に非侵襲性である用途のための改善された製剤
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
DE19907895A1 (de) * 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
ATE283048T1 (de) 1999-12-08 2004-12-15 Pharmacia Corp Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US20060004086A1 (en) * 2000-04-13 2006-01-05 Mayo Foundation For Medical Education And Research Method of reducing Abeta42 and treating diseases
DE10047319A1 (de) * 2000-09-25 2002-04-18 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen, welche durch die Hemmung der Aktivierung des nukleären Transkriptionsfaktors AP-1 therapeutisch beeinflußt werden können
US20040077604A1 (en) * 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
US20030027867A1 (en) * 2001-06-29 2003-02-06 Myriad Genetics, Incorporated Use of R-NSAID compounds for anti-HIV treatment
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
JP2008519784A (ja) * 2004-11-12 2008-06-12 イデア アクチェンゲゼルシャフト 皮膚状態の治療における拡張表面凝集体
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
US9125899B1 (en) 2010-06-17 2015-09-08 Stc.Unm Modulators of GTPases and their use
EP2468270A1 (en) 2010-12-21 2012-06-27 GALENpharma GmbH (R)-2-(3-fluoro-4-phenylphenyl)propionic acid for use in the treatment of skin diseases
WO2013059245A1 (en) 2011-10-17 2013-04-25 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
US20150183737A1 (en) * 2012-07-20 2015-07-02 Vanderbilt University Compositions and methods for substrate-selective inhibition of endocannabinoid oxygenation
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
CN113712960B (zh) * 2021-09-23 2023-04-07 南京医科大学 R-酮咯酸在防治主动脉夹层和主动脉瘤中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4028906A1 (de) * 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
DE4319438C1 (de) * 1993-06-11 1994-06-01 Gerd Dr Dr Geislinger Arzneimittel auf der Grundlage von Ketoprofen zur Bekämpfung von Schmerzen und/oder Entzündungen und/oder Fieber an Menschen und Tieren
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
IT1298214B1 (it) * 1998-01-28 1999-12-20 Dompe Spa Sali dell'acido (r) 2-(3-benzoilfenil) propionico e loro composizioni farmaceutiche.

Also Published As

Publication number Publication date
ATE353010T1 (de) 2007-02-15
EP1143958B1 (en) 2007-01-31
EP1143958A2 (en) 2001-10-17
ES2281981T3 (es) 2007-10-01
JP2002524415A (ja) 2002-08-06
CA2342628C (en) 2009-07-07
WO2000013684A2 (en) 2000-03-16
US6472433B2 (en) 2002-10-29
US20010012849A1 (en) 2001-08-09
EP1143958B8 (en) 2007-05-23
DE69933049D1 (de) 2006-10-12
EP1143958A3 (en) 2002-08-21
PT1143958E (pt) 2007-04-30
CY1106541T1 (el) 2012-01-25
CN1391470A (zh) 2003-01-15
WO2000013684A3 (en) 2002-05-30
CA2342628A1 (en) 2000-03-16
DK1143958T3 (da) 2007-04-10
AU6026099A (en) 2000-03-27

Similar Documents

Publication Publication Date Title
DE69933049T2 (de) Pharmazeutische zusammensetzung und verwendung von rnsaid zur behandlung der entzündung
DE69636413T2 (de) Verabreichungsmedium für analgetische, entzündungshemmende und antipyretische wirkstoffe und pharmazeutische zusammensetzungen enthaltend solches medium und wirkstoffe
DE69309492T2 (de) Antipyretische und analgetische zusammensetzungen, die optisch reines r-ketorolac enthalten
DE69634776T2 (de) Verwendung eines r-nsaid als chemoschützendes mittel zur behandlung von colorektalkrebs
DE69805202T2 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
DE60118547T2 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
JP6027722B2 (ja) 脳梗塞の予防及び治療用医薬品の製造におけるｌ−ブチルフタリドの使用
AT409083B (de) Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
DE68912459T2 (de) Verwendung von Thromboxan-A2-Rezeptorantagonisten zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Hautkrankheiten.
JPS58222016A (ja) 局所投与に適する補酵素ｑ↓１↓０を含有する医薬組成物とその製剤法
LV10048B (en) Medical agent and method for producing thereof
DE3390114C2 (https=)
DE69328838T2 (de) Antipyretische und analgetische verfahren und zusammensetzungen, die optisch reines r-etodolac enthalten
DE69832695T2 (de) Verwendung von r-enantiomeren nichtsteroidaler entzündungshemmer zur vorbeugung der alzheimerschen krankheit
DE3390116C2 (de) Verbesserte, Koffein enthaltende, analgetische und antiinflammatorische Mittel
EP0250648A2 (de) Pharmazeutisches Präparat zur verzögerten Freigabe von Ibuprofen
DE4220851A1 (de) Verwendung von schwefel enthaltenden carbonsaeuren zur bekaempfung von pathophysiologisch bedingten erregungsstoerungen und von hierdurch bedingten erkrankungen sowie von allergischen erkrankungen sowie die herstellung entsprechender arzneimittel
DE69721838T2 (de) 1-[1-(4-chlorphenyl)cyclobutyl]-3-methylbutyl amin derivate zur senkung von harnsäurespiegeln beim menschen
DE3883606T2 (de) Verwendung von Fluoxetin zur Behandlung des Diabetes.
DE69413090T2 (de) Verwendung von 5-Amino-Phthaloylhydrazid als antihypoxisches und defensives Mittel
DE69817379T2 (de) Pharmazeutische zubereitungen enthaltend ibuprofen und domperidon zur behandlung von migräne
EP1154766B1 (de) Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln, zur behandlung von erkrankungen bei mensch und tier, welche durch die hemmung der aktivierung von nf-kappa b therapeutisch beeinflusst werden können
DE3517820A1 (de) Pharmazeutische praeparate mit antihypertensiver und kardioprotektiver wirkung
DE69816520T2 (de) Behandlung von durch Einzeller verursachte Infektionen
DE4319438C1 (de) Arzneimittel auf der Grundlage von Ketoprofen zur Bekämpfung von Schmerzen und/oder Entzündungen und/oder Fieber an Menschen und Tieren

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation